

# Daniela Ungureanu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6852340/publications.pdf>

Version: 2024-02-01

35  
papers

2,297  
citations

304368

22  
h-index

377514

34  
g-index

35  
all docs

35  
docs citations

35  
times ranked

2746  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular thermal shift assay (CETSA) for determining the drug binding affinity using Ba/F3 clones stably expressing receptor pseudokinases. <i>Methods in Enzymology</i> , 2022, 667, 339-363.	0.4	2
2	New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 276.	2.4	4
3	STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells. <i>Translational Oncology</i> , 2021, 14, 101027.	1.7	9
4	Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
5	Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. <i>Cancers</i> , 2021, 13, 3727.	1.7	13
6	Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. <i>Cell Death and Disease</i> , 2020, 11, 790.	2.7	38
7	Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. <i>Molecular Cell</i> , 2020, 79, 390-405.e7.	4.5	56
8	Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways. <i>Cells</i> , 2019, 8, 812.	1.8	30
9	Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. <i>Oncogene</i> , 2019, 38, 3288-3300.	2.6	39
10	Interaction between ROR1 and MuSK activation complex in myogenic cells. <i>FEBS Letters</i> , 2018, 592, 434-445.	1.3	8
11	Expression Analysis of Platinum Sensitive and Resistant Epithelial Ovarian Cancer Patient Samples Reveals New Candidates for Targeted Therapies. <i>Translational Oncology</i> , 2018, 11, 1160-1170.	1.7	19
12	Targeting Wnt signaling pseudokinases in hematological cancers. <i>European Journal of Haematology</i> , 2018, 101, 457-465.	1.1	13
13	Targeting ROR1 identifies new treatment strategies in hematological cancers. <i>Biochemical Society Transactions</i> , 2017, 45, 457-464.	1.6	28
14	Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 618-621.	1.3	38
15	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. <i>Blood Advances</i> , 2017, 1, 2257-2268.	2.5	25
16	ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4642-4647.	3.3	95
17	Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2). <i>Journal of Biological Chemistry</i> , 2015, 290, 27261-27270.	1.6	70
18	Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses. <i>Biochemical Journal</i> , 2014, 458, 395-405.	1.7	33

#	ARTICLE	IF	CITATIONS
19	A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. <i>Biochemical Journal</i> , 2014, 457, 323-334.	1.7	241
20	The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 1835-1841.	1.1	19
21	Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase. <i>Nature Structural and Molecular Biology</i> , 2014, 21, 579-584.	3.6	132
22	Analysis of steady-state Förster resonance energy transfer data by avoiding pitfalls: Interaction of JAK2 tyrosine kinase with N-methylanthraniloyl nucleotides. <i>Analytical Biochemistry</i> , 2013, 442, 213-222.	1.1	6
23	New insights into the structure and function of the pseudokinase domain in JAK2. <i>Biochemical Society Transactions</i> , 2013, 41, 1002-1007.	1.6	35
24	Structure-function analysis indicates that sumoylation modulates DNA-binding activity of STAT1. <i>BMC Biochemistry</i> , 2012, 13, 20.	4.4	23
25	Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. <i>Nature Structural and Molecular Biology</i> , 2012, 19, 754-759.	3.6	196
26	The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. <i>Nature Structural and Molecular Biology</i> , 2011, 18, 971-976.	3.6	237
27	Analysis of Jak2 Catalytic Function by Peptide Microarrays: The Role of the JH2 Domain and V617F Mutation. <i>PLoS ONE</i> , 2011, 6, e18522.	1.1	32
28	Sumoylation of <i>Drosophila</i> Transcription Factor STAT92E. <i>Journal of Innate Immunity</i> , 2010, 2, 618-624.	1.8	19
29	MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1. <i>Biochemical Journal</i> , 2008, 409, 179-185.	1.7	39
30	SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. <i>Blood</i> , 2005, 106, 224-226.	0.6	86
31	SLIM Trims STATs: Ubiquitin E3 Ligases Provide Insights for Specificity in the Regulation of Cytokine Signaling. <i>Science Signaling</i> , 2005, 2005, pe49-pe49.	1.6	22
32	PIAS proteins promote SUMO-1 conjugation to STAT1. <i>Blood</i> , 2003, 102, 3311-3313.	0.6	135
33	Regulation of Jak2 through the Ubiquitin-Proteasome Pathway Involves Phosphorylation of Jak2 on Y1007 and Interaction with SOCS-1. <i>Molecular and Cellular Biology</i> , 2002, 22, 3316-3326.	1.1	226
34	IL-15-IgG2b fusion protein accelerates and enhances a Th2 but not a Th1 immune response in vivo, while IL-2-IgG2b fusion protein inhibits both. <i>European Journal of Immunology</i> , 1998, 28, 3312-3320.	1.6	26
35	Interleukin-15 protects from lethal apoptosis in vivo. <i>Nature Medicine</i> , 1997, 3, 1124-1128.	15.2	303